Frequency and proportion of cases of breast cancer recurrence and matched controls within group strata (I) expressing the estrogen receptor and receiving at least one year of tamoxifen therapy (ERP+/TAM+), or (II) not expressing the estrogen receptor, never receiving tamoxifen therapy, and surviving at least one year after diagnosis (ERP−/TAM−). This evidence concerns the gene ESR1 and breast carcinoma.